 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
7 December 1999 | Volume 131 Issue 11 | Pages 813-821
Background: Tests for resistance to HIV drugs are available for clinical use; however, their predictive value has not been fully assessed.
Objectives: To determine HIV-1 genotypic predictors of a virologic response to saquinavir–ritonavir therapy in patients in whom at least one previous protease inhibitor-containing regimen had failed and to compare the predictive value of baseline genotype with that of standard clinical evaluation.
Design: Retrospective clinical cohort study.
Setting: University-based HIV clinic.
Patients: 54 HIV-1-infected adults treated with saquinavir–ritonavir who had experienced virologic failure while receiving a protease inhibitor-containing regimen for at least 3 months.
Measurements: HIV-1 reverse transcriptase and protease gene sequences, CD4 cell counts, clinical characteristics, detailed antiretroviral treatment history, and plasma HIV-1 RNA levels at baseline and at three follow-up time points (median, 4, 12, and 26 weeks). Virologic failure was defined as a plasma HIV RNA level greater than 1000 copies/mL.
Results: In 22 patients (41%), a plasma HIV-1 RNA level less than 500 copies/mL was achieved by week 12; in 15 patients (28%), this response was maintained through week 26. Clinical characteristics predicting a poorer response included a diagnosis of AIDS, lower CD4 cell count, and higher plasma HIV RNA level (P < 0.03). Number of previous nucleoside reverse transcriptase inhibitors, previous protease inhibitor therapy, and duration of previous protease inhibitor therapy were predictors of poorer response (P < 0.01). Multivariate regression models revealed that protease mutations present at the initiation of saquinavir–ritonavir therapy were the strongest predictors of virologic response. A model of clinical features explained up to 45% of the variation in virologic outcomes by week 12, whereas the explained variance was 71% when genotypic predictors were included.
Conclusions: In patients in whom protease inhibitor-containing antiretroviral therapy fails, HIV-1 genotype is predictive of virologic response to subsequent therapy. This predictive capacity adds to that of standard clinical evaluation.
Author and Article Information
From Stanford University School of Medicine, Stanford, California.
Acknowledgments: The authors thank Mitch Katz, MD, of the Department of Public Health, San Francisco, for critical review of the manuscript, and John Sninsky, PhD, of Roche Molecular Systems, Alameda, California, for contributing PCR kits and reagents used in the HIV-1 sequencing reactions.
Requests for Reprints: Andrew R. Zolopa, MD, Division of Infectious Diseases and Geographical Medicine, Stanford University School of Medicine, Grant Building, Room S-156, Stanford, CA 94305; e-mail, azolopa{at}stanford.edu.
Current Author Addresses: Drs. Zolopa, Shafer, Warford, Montoya, Hsu, Katzenstein, and Merigan: Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Grant Building Room S-156, Stanford, CA 94305.
Dr. Efron: Department of Statistics, Stanford University, Sequoia Hall, Room 132, Stanford CA 94305. ARTICLE
HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir–ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  G. S. Zaric, A. M. Bayoumi, M. L. Brandeau, and D. K. Owens The Cost-Effectiveness of Counseling Strategies to Improve Adherence to Highly Active Antiretroviral Therapy among Men Who Have Sex with Men Med Decis Making, June 1, 2008; 28(3): 359 - 376. [Abstract] [PDF]
|
|
|
|
 |
|
 A. F. Y. Poon, S. L. Kosakovsky Pond, D. D. Richman, and S. D. W. Frost Mapping Protease Inhibitor Resistance to Human Immunodeficiency Virus Type 1 Sequence Polymorphisms within Patients J. Virol., December 15, 2007; 81(24): 13598 - 13607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Y. W. Tong, J. Mullen, R. Kulasegaram, A. De Ruiter, S. O'Shea, and I. L. Chrystie Genotyping of B and Non-B Subtypes of Human Immunodeficiency Virus Type 1 J. Clin. Microbiol., September 1, 2005; 43(9): 4623 - 4627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-G. Marcelin, I. Cohen-Codar, M. S. King, P. Colson, E. Guillevic, D. Descamps, C. Lamotte, V. Schneider, J. Ritter, M. Segondy, et al. Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1720 - 1726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Scott Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients Am. J. Health Syst. Pharm., April 15, 2005; 62(8): 809 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Sanders, A. M. Bayoumi, V. Sundaram, S. P. Bilir, C. P. Neukermans, C. E. Rydzak, L. R. Douglass, L. C. Lazzeroni, M. Holodniy, and D. K. Owens Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy N. Engl. J. Med., February 10, 2005; 352(6): 570 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-G. Marcelin, C. Dalban, G. Peytavin, C. Lamotte, R. Agher, C. Delaugerre, M. Wirden, F. Conan, S. Dantin, C. Katlama, et al. Clinically Relevant Interpretation of Genotype and Relationship to Plasma Drug Concentrations for Resistance to Saquinavir-Ritonavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4687 - 4692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mo, L. Lu, R. Pithawalla, D. J. Kempf, and A. Molla Complementation in Cells Cotransfected with a Mixture of Wild-Type and Mutant Human Immunodeficiency Virus (HIV) Influences the Replication Capacities and Phenotypes of Mutant Variants in a Single-Cycle HIV Resistance Assay J. Clin. Microbiol., September 1, 2004; 42(9): 4169 - 4174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Garcia-Lerma, H. MacInnes, D. Bennett, H. Weinstock, and W. Heneine Transmitted Human Immunodeficiency Virus Type 1 Carrying the D67N or K219Q/E Mutation Evolves Rapidly to Zidovudine Resistance In Vitro and Shows a High Replicative Fitness in the Presence of Zidovudine J. Virol., July 15, 2004; 78(14): 7545 - 7552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gonzalez, B. Masquelier, H. Fleury, B. Lacroix, A. Troesch, G. Vernet, and J. N. Telles Detection of Human Immunodeficiency Virus Type 1 Antiretroviral Resistance Mutations by High-Density DNA Probe Arrays J. Clin. Microbiol., July 1, 2004; 42(7): 2907 - 2912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Clotet and P. R. Skolnik Comparison of Regimens as Initial Therapy for HIV N. Engl. J. Med., March 4, 2004; 350(10): 1053 - 1054. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Katzenstein Genotype, Phenotype, and Virtual Phenotype: Who Needs What and Why? J Int Assoc Physicians AIDS Care (Chic Ill), October 1, 2003; 2(4): 140 - 146. [PDF]
|
|
|
|
|
|
R. A. Galli, B. Sattha, B. Wynhoven, M. V. O'Shaughnessy, and P. R. Harrigan Sources and Magnitude of Intralaboratory Variability in a Sequence-Based Genotypic Assay for Human Immunodeficiency Virus Type 1 Drug Resistance J. Clin. Microbiol., July 1, 2003; 41(7): 2900 - 2907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Grant, D. R. Kuritzkes, V. A. Johnson, J. W. Mellors, J. L. Sullivan, R. Swanstrom, R. T. D'Aquila, M. Van Gorder, M. Holodniy, R. M. Lloyd Jr., et al. Accuracy of the TRUGENE HIV-1 Genotyping Kit J. Clin. Microbiol., April 1, 2003; 41(4): 1586 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Kuritzkes, R. M. Grant, P. Feorino, M. Griswold, M. Hoover, R. Young, S. Day, R. M. Lloyd Jr., C. Reid, G. F. Morgan, et al. Performance Characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System J. Clin. Microbiol., April 1, 2003; 41(4): 1594 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Watkins, W. Resch, D. Irlbeck, and R. Swanstrom Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors Antimicrob. Agents Chemother., February 1, 2003; 47(2): 759 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Aslanzadeh HIV Resistance Testing: an Update Ann. Clin. Lab. Sci., October 1, 2002; 32(4): 406 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Little, S. Holte, J.-P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, et al. Antiretroviral-Drug Resistance among Patients Recently Infected with HIV N. Engl. J. Med., August 8, 2002; 347(6): 385 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Yeni, S. M. Hammer, C. C. J. Carpenter, D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, et al. Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel JAMA, July 10, 2002; 288(2): 222 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Molla, H. Mo, S. Vasavanonda, L. Han, C. T. Lin, A. Hsu, and D. J. Kempf In Vitro Antiviral Interaction of Lopinavir with Other Protease Inhibitors Antimicrob. Agents Chemother., July 1, 2002; 46(7): 2249 - 2253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Servais, C. Lambert, J.-M. Plesseria, E. Fontaine, I. Robert, V. Arendt, T. Staub, R. Hemmer, F. Schneider, and J.-C. Schmit Longitudinal Use of a Line Probe Assay for Human Immunodeficiency Virus Type 1 Protease Predicts Phenotypic Resistance and Clinical Progression in Patients Failing Highly Active Antiretroviral Therapy Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1928 - 1933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Shafer Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance Clin. Microbiol. Rev., April 1, 2002; 15(2): 247 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kantor, W. J. Fessel, A. R. Zolopa, D. Israelski, N. Shulman, J. G. Montoya, M. Harbour, J. M. Schapiro, and R. W. Shafer Evolution of Primary Protease Inhibitor Resistance Mutations during Protease Inhibitor Salvage Therapy Antimicrob. Agents Chemother., April 1, 2002; 46(4): 1086 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 HIV Drug Resistance Testing: An Update for the Clinician AIDS Clinical Care, October 1, 2001; 2001(1001): 8 - 8. [Full Text]
|
|
|
|
|
|
D. J. Kempf, J. D. Isaacson, M. S. King, S. C. Brun, Y. Xu, K. Real, B. M. Bernstein, A. J. Japour, E. Sun, and R. A. Rode Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients J. Virol., August 15, 2001; 75(16): 7462 - 7469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Erali, S. Page, L. G. Reimer, and D. R. Hillyard Human Immunodeficiency Virus Type 1 Drug Resistance Testing: a Comparison of Three Sequence-Based Methods J. Clin. Microbiol., June 1, 2001; 39(6): 2157 - 2165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J Little Is transmitted drug resistance in HIV on the rise? BMJ, May 5, 2001; 322(7294): 1074 - 1075. [Full Text]
|
|
|
|
|
|
R. W. Shafer, K. Hertogs, A. R. Zolopa, A. Warford, S. Bloor, B. J. Betts, T. C. Merigan, R. Harrigan, and B. A. Larder High Degree of Interlaboratory Reproducibility of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Sequencing of Plasma Samples from Heavily Treated Patients J. Clin. Microbiol., April 1, 2001; 39(4): 1522 - 1529. [Abstract] [Full Text]
|
|
|
|
|
|
J. Servais, C. Lambert, E. Fontaine, J.-M. Plesséria, I. Robert, V. Arendt, T. Staub, F. Schneider, R. Hemmer, G. Burtonboy, et al. Comparison of DNA Sequencing and a Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Patients Failing Highly Active Antiretroviral Therapy J. Clin. Microbiol., February 1, 2001; 39(2): 454 - 459. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Flowers Gay Men and HIV/AIDS Risk Management Health (London) , January 1, 2001; 5(1): 50 - 75. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Sharma Antiretroviral Resistance: Mechanisms, Detection and Clinical Implications Journal of Pharmacy Practice, December 1, 2000; 13(6): 442 - 456. [Abstract] [PDF]
|
|
|
|
|
|
M. S. Hirsch, F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, et al. Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society-USA Panel JAMA, May 10, 2000; 283(18): 2417 - 2426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Petropoulos, N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, et al. A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 Antimicrob. Agents Chemother., April 1, 2000; 44(4): 920 - 928. [Abstract] [Full Text]
|
|
|
|
|
|
J. E. Gallant Strategies for Long-term Success in the Treatment of HIV Infection JAMA, March 8, 2000; 283(10): 1329 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Genotype Testing and Response to Therapy AIDS Clinical Care, February 1, 2000; 2000(201): 4 - 4. [Full Text]
|
|
Article
